Nautilus Biotechnology: Expected net profit in the first quarter of 2025 to rise by 96% to 156% year-on-year.

Jin10 data reported on March 27, NuoTai Bio announced that it expects to achieve a net profit attributable to the parent company owners of 130 million to 170 million yuan in the first quarter of 2025, an increase of 63.6732 million to 103.6732 million yuan compared to the same period last year, representing a year-on-year increase of 96% to 156%. The performance rise is mainly due to the significant increase in sales revenue from the company’s peptide raw materials and other products.